Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial ...

Once-daily therapy achieves up to 4.4% placebo-adjusted weight loss, meets all study endpoints and demonstrates favourable ...

Despite missing primary endpoints, the endocannabinoid modulator demonstrated encouraging pain score improvements in subgroup ...

Merck’s largest life science investment in Asia-Pacific to date expands regional manufacturing capacity Integrated digital ...

CEO Robert Wonsang Yu shared the company's vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX ...

The timed run also reduced total review time from almost 26 hours for Enveda’s four reviewers to just under three hours, ...

Investigational oral therapy targeting rhodopsin protein misfolding is currently undergoing Phase 1/2 clinical evaluation for ...

Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76 ...

Accord now holds two pegfilgrastim biosimilars in one market, its in-house Ennumo and the acquired Udenyca. Owning both the ...

TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours ...

MEPSGEN US, Inc., a global innovator in drug delivery system platforms, announced the launch of NanoCalibur® Mini, an ...

NMPA accepts new indication application following Phase II MIZAR-003 results demonstrating a 57% reduction in the risk of ...